ENTA
BEARISH
$13.77
Live
Enanta Pharmaceuticals, Inc. · NASDAQ
Target $18.5
(+34.4%)
$4.12
52W Range
$17.15
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$399.6M
P/E
N/A
ROE
-60.0%
Profit margin
-106.8%
Debt/Equity
1.53
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
60%
ENTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Low profit margin of -106.8%
Weak financial trend (Piotroski F-Score: 3/9)
Weak ROE of -60.0%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
50
50
30
30
0
AI Verdict
ENTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -106.8%, Weak financial trend (Piotroski F-Score: 3/9)
Confidence
20%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -71.8% over 5Y and +208.7% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -60.0%.
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$13.77
Analyst Target
$18.5
Upside/Downside
+34.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ENTA and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
Primary
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
ENT
Enanta Pharmaceuticals, Inc.
Primary
5Y
-71.8%
3Y
-64.9%
1Y
+208.7%
6M
+21.9%
1M
-0.9%
1W
+6.2%
AKB
Akebia Therapeutics, Inc.
Peer
5Y
-59.4%
3Y
+113.8%
1Y
-13.6%
6M
-50.5%
1M
-5.8%
1W
+15.0%
AGL
agilon health, inc.
Peer
5Y
-96.8%
3Y
-95.0%
1Y
-73.1%
6M
-51.9%
1M
+41.4%
1W
-2.8%
AUN
Auna SA
Peer
5Y
-41.0%
3Y
-41.0%
1Y
-30.8%
6M
-9.7%
1M
+21.7%
1W
+22.2%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-6.24
PEG Ratio
N/A
P/B Ratio
3.16
P/S Ratio
5.97
EV/Revenue
6.08
EV/EBITDA
-5.97
Market Cap
$399.6M
Profitability
Profit margins and return metrics
Profit Margin
-106.8%
Operating Margin
-60.45%
Gross Margin
100.0%
ROE
-60.01%
ROA
-13.47%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+9.76%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.53
High debt
Current Ratio
4.44
Strong
Quick Ratio
4.34
Excellent
Cash/Share
$6.4
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-60.5%
Net Margin
-64.1%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
1.60x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-09
$-0.42
+52.0% surprise
2025-11-17
$-0.87
+13.9% surprise
2025-08-11
$-0.85
+4.0% surprise
Healthcare Sector Comparison
Comparing ENTA against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-60.01%
This Stock
vs
-44.08%
Sector Avg
+36.1%
(Excellent)
Profit Margin
-106.8%
This Stock
vs
-19.57%
Sector Avg
+445.8%
(Superior)
Debt to Equity
1.53
This Stock
vs
5.1
Sector Avg
-70.1%
(Less Debt)
Revenue Growth
9.8%
This Stock
vs
108.17%
Sector Avg
-90.9%
(Slower)
Current Ratio
4.44
This Stock
vs
3.39
Sector Avg
+31.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | Compare |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
ENTA
Enanta...
BEARISH
Mkt Cap
$400M
P/E
-
ROE
-60.0%
Price
$13.77
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-12 | LULY JAY R | Chief Executive Officer | Stock Award | 20,000 | - |
| 2026-02-12 | OR YAT SUN | Officer | Stock Award | 6,875 | - |
| 2026-02-12 | KOWALSKY MATTHEW PAUL | Officer | Stock Award | 5,493 | - |
| 2026-02-12 | KIEFFER TARA LYNN | Officer | Stock Award | 6,562 | - |
| 2026-02-12 | LUU BRENDAN | Officer | Stock Award | 6,562 | - |
| 2026-02-12 | ROTTINGHAUS SCOTT T. | Officer | Stock Award | 6,875 | - |
| 2025-12-05 | LULY JAY R | Chief Executive Officer | Sale | 4,743 | $67,493 |
| 2025-12-05 | TROUT HARRY R III | Officer | Sale | 542 | $7,713 |
| 2025-12-05 | OR YAT SUN | Officer | Sale | 2,390 | $34,010 |
| 2025-12-05 | KIEFFER TARA LYNN | Officer | Sale | 2,106 | $29,968 |
| 2025-12-05 | LUU BRENDAN | Officer | Sale | 1,394 | $19,837 |
| 2025-12-05 | ROTTINGHAUS SCOTT T. | Officer | Sale | 798 | $11,356 |
| 2025-12-05 | CAPPS KATHLEEN S. CPA | Officer | Sale | 323 | $4,596 |
| 2025-12-02 | TROUT HARRY R III | Officer | Sale | 380 | $5,305 |
| 2025-12-02 | CAPPS KATHLEEN S. CPA | Officer | Sale | 207 | $2,890 |
LULY JAY R
Chief Executive Officer
2026-02-12
20,000 shares
OR YAT SUN
Officer
2026-02-12
6,875 shares
KOWALSKY MATTHEW PAUL
Officer
2026-02-12
5,493 shares
KIEFFER TARA LYNN
Officer
2026-02-12
6,562 shares
LUU BRENDAN
Officer
2026-02-12
6,562 shares
ROTTINGHAUS SCOTT T.
Officer
2026-02-12
6,875 shares
LULY JAY R
Chief Executive Officer
2025-12-05
4,743 shares
·
$67,493
TROUT HARRY R III
Officer
2025-12-05
542 shares
·
$7,713
OR YAT SUN
Officer
2025-12-05
2,390 shares
·
$34,010
KIEFFER TARA LYNN
Officer
2025-12-05
2,106 shares
·
$29,968
LUU BRENDAN
Officer
2025-12-05
1,394 shares
·
$19,837
ROTTINGHAUS SCOTT T.
Officer
2025-12-05
798 shares
·
$11,356
CAPPS KATHLEEN S. CPA
Officer
2025-12-05
323 shares
·
$4,596
TROUT HARRY R III
Officer
2025-12-02
380 shares
·
$5,305
CAPPS KATHLEEN S. CPA
Officer
2025-12-02
207 shares
·
$2,890
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
HC Wainwright & Co.
2026-02-10
Buy
Buy
HC Wainwright & Co.
2026-01-09
Buy
Buy
JP Morgan
2025-11-14
Overweight
Past News Coverage
Recent headlines mentioning ENTA from our newsroom.
Newest → oldest
No matching news yet.